• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WEI Xianming,WANG Lei,CHENG Ze'neng.Advances in aspirin-based therapies for peripheral arterial disease: Monotherapy and combination strategies[J].Journal Of Pharmaceutical Research,2026,45(6):681-688[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1026times   Download 582次 QR Code for this article
Scan with your phone!
阿司匹林及其联合用药治疗外周动脉疾病的研究进展
韦先铭1,王磊2,程泽能1,2
Font:Larger+|Default|Smaller-
(1.中南大学湘雅药学院,湖南 长沙 410013;2.湖南慧泽生物医药科技有限公司,湖南 长沙 410017)
摘要:
阿司匹林是症状型外周动脉疾病(PAD)抗栓治疗的基础用药,但其单药治疗在高危患者中疗效有限,联合用药已成为重要策略并积累了大量临床证据。现有综述多聚焦PAD已有联合方案,缺乏以阿司匹林为核心的系统综述。本文以阿司匹林为中心,总结其单药及联用治疗的研究进展,重点分析关键临床试验证据。其中COMPASS及VOYAGER PAD研究证实,利伐沙班联合阿司匹林为特定PAD患者的最佳联合策略,进一步巩固了阿司匹林在联合抗栓中的核心地位。目前针对利伐沙班-阿司匹林复方制剂研究尚属空白,该剂型的研发有望改善临床依从性,推动抗栓策略的普及应用。
关键词:  阿司匹林  联合用药  外周动脉疾病  抗栓策略  固定剂量复方制剂
DOI:10.13506/j.cnki.jpr.2026.06.011
基金项目:湖南省科技创新类湖湘青年英才项目(No.2024RC3259)
Received Date:December 23, 2025   Revision Date:February 28, 2026  
Advances in aspirin-based therapies for peripheral arterial disease: Monotherapy and combination strategies
WEI Xianming1,WANG Lei2,CHENG Ze'neng1,2
(1.Xiangya School of Pharmaceutical Sciences,Central South University,Changsha 410000,China;2.Hunan Huize Bio-pharmaceutical Co.,Ltd.,Changsha 410000,China)
Abstract:
Aspirin serves as the cornerstone of antithrombotic therapy for symptomatic peripheral arterial disease (PAD). However, its monotherapy demonstrates limited efficacy in high-risk patients, making combination therapy a crucial strategy supported by substantial clinical evidence. Existing reviews predominantly focus on various PAD combination regimens, lacking systematic reviews centered on aspirin. This paper centers on aspirin to summarize research progress in its monotherapy and combination therapy, with a focus on analyzing key clinical trial evidence. The COMPASS and VOYAGER PAD studies confirmed that rivaroxaban combined with aspirin represents the optimal combination strategy for specific PAD patients, further solidifying aspirin's central role in combined antithrombotic therapy. Currently, no studies exist on fixed dose combination formulations of rivaroxaban and aspirin. Developing such formulations holds promise for improving clinical adherence and advancing the widespread adoption of antithrombotic strategies.
Key words:  Aspirin  Combination therapy  Peripheral arterial disease(PAD)  Antithrombotic strategy  Fixed dose combination
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.